Stock info Roche | Filter  Basic-Info

Stock: Roche (Swiss large cap), ISIN: CH0012032048

Last Price 225.05 Max Price 292.80
Min Price 224.90 1 Year return -40.64
Avg. Target 278.67 Expected Return 23.82 %
Sector Health Care Subsector Pharmaceuticals
Sell 1 Rating Star full 12x12Star full 12x12Star full 12x12
Hold 0 Concensus Cons sellCons buy
Buy 2
Annual report 2015

Loading...

Contact info:Street: 1 DNA WayZip Code: South San City: BASEL,Country: SwitzerlandPhone: 1 650 225 5566Email: RocheIRNA@gene.comWebsite: www.roche.comCEO: Dr Severin SchwanCFO: Dr. Alan Hippe

Sector Review Roche

Loading...
Year Turnover Total sector Market share
2019 61,466 615,634 9.98 %
2020 58,323 638,070 9.14 %
2021 62,801 727,968 8.63 %
2022 63,281 787,273 8.04 %
2023 0 0 0.00 %

Advice Roche

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
February 21, 2024 JP Morgan Roche Sell 210.00 -7.17 %
February 20, 2024 Morgan Stanley Roche Hold 250.00 9.98 %
February 20, 2024 Berenberg Roche Buy 265.00 15.08 %
January 15, 2024 UBS Roche Hold 278.00 19.05 %
January 03, 2024 Jefferies & Co. Roche Hold 275.00 18.16 %
October 21, 2023 Deutsche Bank Roche Sell 225.00 -0.02 %
October 21, 2023 DZ Bank Roche Buy 291.00 22.66 %
July 14, 2023 HSBC Roche Buy 320.00 29.67 %
January 15, 2024 JP Morgan Roche Sell 230.00 2.15 %
October 31, 2023 JP Morgan Roche Sell 245.00 8.14 %
October 12, 2023 Jefferies & Co. Roche Hold 285.00 21.04 %
October 11, 2023 Morgan Stanley Roche Hold 290.00 22.40 %
October 10, 2023 JP Morgan Roche Sell 260.00 13.44 %
June 10, 2023 JP Morgan Roche Sell 275.00 18.16 %
June 10, 2023 Jefferies & Co. Roche Hold 305.00 26.21 %
May 03, 2023 Morgan Stanley Roche Hold 320.00 29.67 %
March 28, 2023 Barclays Roche Buy 270.00 16.65 %
February 21, 2023 Morgan Stanley Roche Hold 315.00 27.87 %
January 22, 2023 UBS Roche Hold 315.00 20.37 %
January 22, 2023 Goldman Sachs Roche Buy 429.00 41.53 %
January 21, 2023 Deutsche Bank Roche Sell 265.00 5.34 %
January 05, 2023 Jefferies & Co. Roche Hold 325.00 22.51 %
January 03, 2023 JP Morgan Roche Sell 275.00 11.16 %
December 29, 2022 Barclays Roche Buy 400.00 38.92 %
December 07, 2022 Morgan Stanley Roche Hold 330.00 23.95 %
November 15, 2022 Cowen and Company Roche Hold
October 08, 2022 Deutsche Bank Roche Buy 300.00 16.77 %
October 08, 2022 Goldman Sachs Roche Buy 446.50 44.08 %
September 15, 2022 Credit Suisse Roche Buy 375.00 32.29 %
September 14, 2022 Berenberg Roche Buy 380.00 33.18 %
September 10, 2022 Jefferies & Co. Roche Buy 375.00 30.81 %
September 10, 2022 Deutsche Bank Roche Buy 325.00 20.17 %
July 17, 2022 Berenberg Roche Buy 350.00 23.54 %
May 13, 2022 Jefferies & Co. Roche Buy 360.00 22.12 %
April 27, 2022 Sanford C. Bernstein & Co Roche Buy 430.00 34.71 %
April 27, 2022 Barclays Roche Buy 450.00 37.61 %
April 27, 2022 Credit Suisse Roche Hold 370.00 24.12 %
April 27, 2022 Deutsche Bank Roche Buy 425.00 33.94 %
April 26, 2022 ABN AMRO Roche Buy 443.00 36.63 %
April 26, 2022 UBS Roche Sell 345.00 18.54 %



News Roche

2008 best year, 2009 worst year for Roche

Roche-investors have very profitable for long times. Even without dividend payments the stock is one of the outperformers from as well pharmaceutical sector as the Swiss exchange. The received dividends are a cherry on the cake for investors. The matrix above...

Roche inks potential $3B multi-target strategic collaboration with Shape Therapeutics

Roche (OTCQX:RHHBY) has signed a multi-target strategic collaboration and license agreement with Shape Therapeutics. Under the terms of the agreement, Shape is eligible to receive an initial payment as well as development, regulatory and sales milestone...

Analysts expect over 2020 rising revenue Roche

For this year Roche's revenue will be around 61,6 billion CHF. This is according to the average of the analysts' estimates. This is slightly more than 2019's revenue of 61,47 billion CHF. Historical revenues and results Roche plus estimates 2020 SKF The analysts...

Analysts expect revenue increase Roche

Tomorrow the Swiss Roche will report its past quarters results. Over the current book year the total revenue will be 62,25 billion CHF (consensus estimates). This is slightly more than 2018's revenue of 56,85 billion CHF. Historical revenues and results Roche...

Stock Roche goes ahead in Switzerland in terms of dividend yields

Huge dividend Roche Investors in Roche can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the Swiss market. Per share the analysts anticipate on a dividend of 8,7 CHF per share.The...

Annual reports Roche

2017 2018 2019 2020 2021

Profile Roche

Roche

(CH0012032048)/ ROG

Roche's headquarter is based in BASEL,. The core activities of Roche are in the pharmaceutical sector. Roche is leaded by CEO Dr Severin Schwan The CFO of Roche the company is Dr. Alan Hippe. Over the past 10 years the global pharmaceutical companies gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year was a good investment year for Roche investors

The stock lost over the past 12 months at around 14 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 66 percent. Roche's revenues between 2011 and 2015 were relatively steady and moved between 45,5 billion CHFF and 48,15 billion CHFF. Roche's net results between 2011 and 2015 were relatively steady and moved between 10,48 billion CHFF and 11,04 billion CHFF.

Over the past 5 years the Swiss company paid out dividends. Over the past 5 years Roche's dividend yield was at around 38,05 percent per year. Over the period 2011-2015 Roche raised it's dividends per share each year. Based on the yearly higher dividend payments Roche is a kind of dividend aristocrat.

At the end of 2015 the company had around 88,51 thousand people employed.

Roche' balance mostly consists of equity

At the end of 2015 the Swiss company's balance sheet was worth 75,76 billion CHFF. At the end of 2015 the total debt positon equaled 54,78 billion CHFF. This is around 72,31 percent of the total balance sheet. At the end of 2016 the Swiss company was traded with a price/earnings-ratio of around 22. So investors paid 22 times the company's 2015's EPS. Based on it's price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 231,98 billion CHFF. At the end of 2015 the Swiss company had around 851 million stocks listed.

All Roche's financial reports are available here. More information about Roche can be found it's website. .


Results Roche

Results
2015
2016
2017
2018
2019
2020
Revenue
48,145
50,576
53,299
56,846
61,466
58,323
Costs
39,283
41,001
44,667
46,347
47,971
44,029
Profit
8,862
9,575
8,632
10,499
13,495
14,294
Margin of profit
18.41
18.93
16.20
18.47
21.96
24.51
ROI
42.24
40.04
32.65
38.01
41.21
39.33

Balance Roche

Balance
2015
2016
2017
2018
2019
2020
Equity
20,979
23,911
26,441
27,622
32,747
36,341
Debt
54,784
52,908
50,235
50,895
50,344
49,797
Total assets
75,763
76,819
76,676
78,517
83,091
86,138
Solvency
27.69
31.13
34.48
35.18
39.41
42.19
Cash
9,171
9,107
11,997
13,118
11,858
12,334
Cashflow
15,251
15,001
18,024
19,979
22,385
18,566
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.28
0.28
0.36
0.39
0.44
0.37

Details Roche

Details
2016
2017
2018
2019
2020
Price
276.40
232.60
246.50
243.40
314.00
Eps
11.13
10.04
12.21
15.62
16.52
Price/earnings-ratio
24.83
23.17
20.19
15.58
13.62
Dividend
8.20
8.30
8.70
9.00
9.10
Dividend %
2.97 %
3.57 %
3.53 %
3.70 %
4.04 %
Payout %
0.74
0.83
0.71
0.58
0.55
Book value
34.56
38.11
39.78
47.07
52.43
Market to book
0.13
0.16
0.16
0.19
0.23
Cashflow per stock
21.68
25.98
28.77
32.17
26.79
Stocks
692
694
694
696
693
Market Cap
191.248.80
161.389.44
171.176.50
169.347.01
155.988.01

Dividend Roche


Price info Roche

Date
Price
22 Mar 2024
225.05
18 Mar 2024
229.60
15 Mar 2024
232.40
12 Mar 2024
244.75
11 Mar 2024
238.20
09 Mar 2024
238.20
07 Mar 2024
235.90
01 Mar 2024
231.95
29 Feb 2024
231.00
27 Feb 2024
229.15
22 Feb 2024
230.85
21 Feb 2024
232.20
20 Feb 2024
232.00
15 Feb 2024
227.20
14 Feb 2024
228.50
13 Feb 2024
227.50
09 Feb 2024
224.90
08 Feb 2024
224.90
07 Feb 2024
230.55
06 Feb 2024
230.50
05 Feb 2024
234.10
01 Feb 2024
247.10
31 Jan 2024
247.10
30 Jan 2024
246.75
27 Jan 2024
247.45
25 Jan 2024
245.15
24 Jan 2024
243.75
23 Jan 2024
247.80
16 Jan 2024
250.85
11 Jan 2024
253.90